Last reviewed · How we verify

NCT06659471

Brief Title: a Clinical Study to Assess Gingivitis

Completed NA Last updated 26 October 2024
What this trial tests

NA trial testing 0.76% Sodium Monofluorophosphate Dentifrice in Gingival Diseases in 120 participants. Completed in 6 June 2022.

Timeline
7 March 2022
Primary endpoint
6 June 2022
6 June 2022

Quick facts

Lead sponsorProcter and Gamble
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment120
Start date7 March 2022
Primary completion6 June 2022
Estimated completion6 June 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Procter and Gamble — full company profile →

Who can join

18 and older, any sex, with Gingival Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this learning clinical study is to evaluate the effects of formulation chemistry on gingivitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of 0.76% Sodium Monofluorophosphate Dentifrice

Trials testing the same drug.

Other recruiting trials for Gingival Diseases

Currently open trials in the same condition.

Other Procter and Gamble trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06659471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing